Invion Ltd. · ASX:IVX
Invion — Investor Presentation (September 2024)
25 slides from Invion's investor presentation, Sep 19, 2024
Slide 1: ASX Announcement: Investor Presentation
ASX ANNOUNCEMENT INVESTOR PRESENTATION MELBOURNE (AUSTRALIA) 19 September 2024: Invion Limited (ASX: IVX) (“Invion” or the “Company”) wishes to release the attached presentation, which will be used by the Company’s Executive Chair and Chief Executive Officer, Thian Chew, at various investor meetings
Slide 2: Corporate Presentation September 2024
For personal use only CORPORATE PRESENTATION September 2024 Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases ASX: IVX
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Highlights: Invion at Clinical Inflection Point
COMPANY HIGHLIGHTS INVION AT CLINICAL INFLECTION POINT For personal use only Positive Ph II Clinical-stage life Patent-protected prostate cancer sciences company Photosoft is the results, ongoing listed on the ASX Next-Gen Phase I/II skin that is developing Photodynamic cancer with other Photosoft T
Slide 5: The Photosoft Advantage
THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs There are several approved PDT treatments on For personal use only Photosoft is a minimally invasive modality for the market, but Photosoft is a ground- treating cancer that specifically identifies and breaking technology that ov
Slide 6: Target Diseases and Indications
TARGET DISEASES AND INDICATIONS PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES PRIMARY FOCUS: CANCER (INV043) INFECTIOUS DISEASES For personal use only ▪ Multiple cancer indications ▪ Broad spectrum antimicrobial activity ▪ Ablation and activation of immune response against viruses, bacteria a
Slide 7: Background and Development Pathway
BACKGROUND AND DEVELOPMENT PATHWAY LAYING GROUNDWORK FOR MULTIPLE CLINICAL TRIALS For personal use only Partnership with Peter Mac PoC 2: Complete COVID-19 Lockdowns regression of TNBC Potential in Additional Indications* metastatic PoC 3: INV043 significantly improves GMP cancers Phase Ib/II ICI th
Slide 8: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE For personal use only IVX Photosensitiser for Cancer: INV043 Effective in regressing multiple types of cancer in vivo1 PhotosoftTM ~600x greater photoxicity than Talaporfin (widely used photosensitiser) Photosoft is a
Slide 9: Results and Findings: Cancer
For personal use only RESULTS AND FINDINGS: CANCER Clinical & Preclinical Data
Slide 10: Phase II Prostate Cancer Clinical Trial Using INV043
PHASE II PROSTATE CANCER CLINICAL TRIAL USING INV043 PHASE II INVESTIGATOR-LED PROSTATE CANCER STUDY* Screening: Men between 50-80 years with 1st cohort of COVID-19 Lockdowns: 10 patients For personal use only ▪ Biopsy proven primary prostate cancer, or dropped out. Remaining treated 25 patients but
Slide 11: Phase II Prostate Study Results: Safety Data
PHASE II PROSTATE STUDY RESULTS: SOLID SAFETY DATA NO SERIOUS ADVERSE EVENTS, ONLY MILD SIDE EFFECTS OBSERVED INV043: Safe and Well Tolerated For personal use only INV043 appeared to be safe and well-tolerated when administered sublingually to patients over the 6 cycles of PDT treatments (based on f
Slide 12: Phase II Prostate Study Results: Promising Efficacy Signals
PHASE II PROSTATE STUDY RESULTS: PROMISING EFFICACY SIGNALS 40-44% RESPONSE RATE TO STANDALONE TREATMENT PSMA-PET1 Results INV043 Results 3 Months Post Treatment For personal use only 20 Patients (Cohort 2, n-=16) evaluated using PSMA-PET scan to Number of patients 15 testing positive detect prostat
Slide 13: Theragnostic Potential
THERAGNOSTIC POTENTIAL MULTIPLE CANCERS, PRECISION CANCER TARGETING, PROTECTIVE IMMUNITY SELECTIVE TARGETING PROTECTIVE IMMUNITY For personal use only Control Treated https://inviongroup.com/videos-reports/ • INV043 selectively retained in malignant but not healthy • Triple Negative Breast Cancer (T
Slide 14: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as
Slide 15: Treatment Options: Flexibility for Clinicians
TREATMENT OPTIONS: FLEXIBILITY FOR CLINICIANS MULTIPLE PATHWAYS FOR DRUG AND TARGETED LIGHT DELIVERY INV043 can be administered to multiple target indications via different drug and light delivery options For personal use only ROUTES OF DRUG ADMINISTRATION LIGHT ADMINISTRATION OPTIONS MULTIPLE POTEN
Slide 16: Target Indications and Timeframes
TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA (CALENDAR YEAR) 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER1 Follow up and monitoring Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Anogenital Cancers (Topical) Glioblastoma (Funde
Slide 17: Why Skin Cancer?
WHY SKIN CANCER? ATTRACTIVE CLINICAL TRIAL INDICATION For personal use only Relatively Cost Effective Costs to undertake skin cancer trials typically lower than for other routes of administration (eg, intravenous) Faster Path to Market Trials with topical treatments often quicker to complete due to
Slide 18: Evaluation of NMSC Therapies
EVALUATION OF NMSC THERAPIES1 POTENTIAL TO DISPLACE STANDARD OF CARE Non-Melanoma Skin Cancer (NMSC) Phase I/II Clinical Trial (Adaptive Trial Structure): Addressing the unmet need for one of the world’s most common cancers2 For personal use only GOOD INV043 (Topical) Metvix#/ALA PDT Treatment #by G
Slide 19: Creating Impact for Treating Cancers Globally
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, Works across multiple cancers without need making affordability even to personalise
Slide 20: Future Additional Indications
FUTURE ADDITIONAL INDICATIONS ADDRESSING UNMET NEEDS OF ASIAN-CENTRIC CANCERS, A US$40B MARKET5 Asians comprise 6% of clinical trial patients in For personal use only FDA approved drugs2 … yet 60% of the world is Asian UNDER-REPRESENTATION IN DRUG DEVELOPMENT MISMATCH WITH GLOBAL INCIDENCE Ethnic Br
Slide 21: Infectious Diseases
For personal use only INFECTIOUS DISEASES Commercialisable Pipeline
Slide 22: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL ANTI-MICROBIAL TREATMENTS – WITHOUT RESISTANCE “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” For personal use only World Health Organisation1 Leading Institutions: Viroclinics conducted virus SARS-CoV-2: Omicron tests & ACARE (U
Slide 23: Target Antimicrobial Indications
TARGET ANTIMICROBIAL INDICATIONS COST EFFECTIVE AND ACCELERATED PATHS TO CLINICAL TRIALS HPV PROGRAM FUNDED BY DR.INB PERIODONTAL DISEASE For personal use only HPV distribution profile in women 1 57.7% 44.4% 42.2% 21.4% 3.7% Eastern Asia Central & Sub-Saharan Eastern Western Southern Africa Europe E
Slide 24: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS THIAN CHEW SCOTT CARPENTER EXECUTIVE CHAIRMAN & CEO PROGRAM DIRECTOR For personal use only • Co-Founder, Chronic Airway Therapeutics • Director Business Development, Starpharma • Advisory Board, Stanford Medicine CARE • Program Manager, AusBiotech • E
Slide 25: For personal use only
For personal use only For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 M: +61 409 341 613 E: investor@inviongroup.com E: brendon.lau@inviongroup.com